<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986557</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000650654</org_study_id>
    <secondary_id>CRC-TU-ACE-CMV</secondary_id>
    <secondary_id>53325562</secondary_id>
    <secondary_id>EU-20974</secondary_id>
    <nct_id>NCT00986557</nct_id>
  </id_info>
  <brief_title>T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant</brief_title>
  <official_title>A Randomised Controlled Phase II Trial of the Adoptive Transfer of Selected Cytomegalovirus-Specific Cytotoxic T Lymphocytes (CMV-CTL) After Allogeneic Stem Cell Transplantation (SCT) in Patients at Risk of CMV Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: An infusion of cytomegalovirus-specific T lymphocytes may prevent or reduce&#xD;
      cytomegalovirus infection during the first year after a donor stem cell transplant.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying T-lymphocyte infusion to see how well it&#xD;
      works compared with standard therapy in treating patients at risk of cytomegalovirus&#xD;
      infection after a donor stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the frequency of cytomegalovirus (CMV) reactivation during the first year&#xD;
           after allogeneic stem cell transplantation (ASCT) in patients at risk for CMV infection&#xD;
           treated with adoptive transfer of selected CMV-specific cytotoxic T-lymphocytes.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To monitor CMV-specific immune reconstitution within the first year following ASCT in&#xD;
           these patients.&#xD;
&#xD;
        -  To determine the time to CMV reactivation in these patients.&#xD;
&#xD;
        -  To evaluate the use of antiviral therapy in these patients.&#xD;
&#xD;
        -  To determine the incidence of secondary CMV reactivation and CMV disease in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  To determine the incidence of acute and chronic graft-versus-host disease.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. After undergoing an allogeneic peripheral blood stem&#xD;
      cell transplantation (PBSCT) using an alemtuzumab-based conditioning regimen that also&#xD;
      includes radiotherapy, patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive cytomegalovirus (CMV)-specific cytotoxic T-lymphocyte infusion&#xD;
           on day 21-90 after allogeneic PBSCT.&#xD;
&#xD;
        -  Arm II: Patients undergo standard follow-up care and receive standard antiviral therapy&#xD;
           comprising ganciclovir IV or foscarnet sodium upon detection or confirmation of CMV&#xD;
           reactivation.&#xD;
&#xD;
      Blood samples are collected to assess CMV viral load by quantitative PCR.&#xD;
&#xD;
      After completion of study therapy, patients are followed once a week for 100 days and then&#xD;
      once a month for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18 patients with sibling donors and 21 patients with unrelated&#xD;
      donors are accrued for each arm, resulting in a total of 78 patients accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CMV reactivation in the first year after ASCT measured by quantitative PCR</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>CMV-specific T-cell reconstitution by detection of circulating T-cell responses to CMV in the first year after ASCT</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CMV reactivation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antiviral therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary CMV reactivation and CMV disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic graft-versus-host disease</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Nonneoplastic Condition</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adoptive immunotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>in vitro-treated peripheral blood lymphocyte therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>foscarnet sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganciclovir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>infection prophylaxis and management</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard follow-up care</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Planning allogeneic peripheral blood stem cell transplantation (PBSCT) using a&#xD;
             conditioning regimen containing alemtuzumab and radiotherapy&#xD;
&#xD;
          -  Sibling or matched unrelated donor available&#xD;
&#xD;
               -  Patients and donor matched for ≥ one of the following HLA alleles:&#xD;
&#xD;
                    -  HLA-A*0101&#xD;
&#xD;
                    -  HLA*0201&#xD;
&#xD;
                    -  HLA-A*1101&#xD;
&#xD;
                    -  HLA-A*2402&#xD;
&#xD;
                    -  HLA-B*0702&#xD;
&#xD;
                    -  HLA-B*0801&#xD;
&#xD;
                    -  HLA-B*3502&#xD;
&#xD;
               -  No donors whose stem cells have already been collected and cryopreserved prior to&#xD;
                  transplant&#xD;
&#xD;
          -  Patient and donor must be CMV seropositive&#xD;
&#xD;
          -  Stem cell harvests ≥ 4.0 x 10^6 CD34 cells/kg&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior bone marrow transplantation&#xD;
&#xD;
          -  No concurrent participation in another therapeutic transplantation study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2SG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick Chen, MD</last_name>
      <phone>44-121-253-4174</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>cytomegalovirus infection</keyword>
  <keyword>graft versus host disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
    <mesh_term>Foscarnet</mesh_term>
    <mesh_term>Phosphonoacetic Acid</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

